Published in J Clin Virol on November 01, 2004
Development of an internal positive control for rapid diagnosis of avian influenza virus infections by real-time reverse transcription-PCR with lyophilized reagents. J Clin Microbiol (2006) 1.55
NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog (2011) 1.52
Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol (2009) 1.43
Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev Technol (2014) 1.13
Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol (2011) 1.11
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet (2010) 1.02
Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity. J Virol (2010) 0.98
The development of a qualitative real-time RT-PCR assay for the detection of hepatitis C virus. Eur J Clin Microbiol Infect Dis (2008) 0.97
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. J Virol (2015) 0.85
Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol (2015) 0.82
Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PLoS One (2013) 0.81
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J Virol (2015) 0.80
Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol J (2009) 0.78
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. PLoS One (2015) 0.77
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents. PLoS One (2016) 0.76
The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. PLoS One (2014) 0.76
Alginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infections. PLoS One (2014) 0.76
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. J Virol (2016) 0.76
Specific ssDNA concentration in liver tissue as an index of apoptosis in hepatitis C virus-infected patients. World J Gastroenterol (2005) 0.75
Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Sci Rep (2016) 0.75
Development of an In-House TaqMan Real Time RT-PCR Assay to Quantify Hepatitis C Virus RNA in Serum and Peripheral Blood Mononuclear Cells in Patients With Chronic Hepatitis C Virus Infection. Hepat Mon (2015) 0.75
Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Clin Exp Immunol (2010) 0.75
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Hepatitis E. Lancet (2012) 4.43
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (2003) 2.23
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS (2008) 2.04
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem (2006) 1.78
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol (2007) 1.69
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol (2006) 1.63
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol (2010) 1.60
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog (2011) 1.52
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Does chronic hepatitis E virus infection exist in immunocompetent patients? Hepatology (2014) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol (2011) 1.47
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol (2004) 1.44
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol (2009) 1.43
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet (2003) 1.40
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol (2006) 1.39
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med (2004) 1.39
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol (2007) 1.34
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology (2012) 1.34
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (2010) 1.32
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol (2006) 1.31
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol (2009) 1.30
Potential exposure to hepatitis C virus through accidental blood contact in interventional radiology. J Vasc Interv Radiol (2003) 1.29
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology (2012) 1.26
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS (2003) 1.24
Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr (2010) 1.24
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol (2009) 1.24
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS (2004) 1.22
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol (2006) 1.22
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther (2004) 1.19
Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS (2005) 1.19
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol (2010) 1.17
Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol (2010) 1.16
Genotypic prediction of HIV-1 subtype D tropism. Retrovirology (2011) 1.16
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther (2011) 1.16
Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol (2010) 1.15
Hepatitis E virus infections in blood donors, France. Emerg Infect Dis (2014) 1.15
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther (2004) 1.14
Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol (2009) 1.13
Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis (2011) 1.13
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS (2006) 1.11
Genotype 3 diversity and quantification of hepatitis E virus RNA. J Clin Microbiol (2012) 1.11
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother (2013) 1.10
Hepatitis C virus infection among pregnant women in Yaounde, Cameroon: prevalence, viremia, and genotypes. J Med Virol (2003) 1.09
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother (2010) 1.09
Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol (2012) 1.09
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis (2004) 1.09
Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (2005) 1.08
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother (2011) 1.07